From a database of 202 women with HR+/HER2− ABC who received treatment with fulvestrant from 2005 to 2017 at the 3 participating Institutions were retrieved 74 patients who underwent a diagnostic biopsy for advanced or metastatic disease before treatment. This evidence concerns the gene HR and metastatic neoplasm.